Ampicillin is the preferred antibiotic for most Enterococcus faecalis urinary tract infections when the strain tests susceptible to it, which the majority still do. For uncomplicated lower UTIs, nitrofurantoin and fosfomycin are effective oral alternatives. What makes treating these infections more complicated than a typical UTI is that E. faecalis shrugs off many of the antibiotics doctors commonly reach for first, including all cephalosporins, and its talent for forming biofilms on catheters can make eradication especially stubborn.
First-Line Antibiotics for Uncomplicated Infections
When a urine culture comes back positive for E. faecalis and you have symptoms of a straightforward lower UTI, the treatment options are relatively narrow compared to more common UTI pathogens like E. coli. Ampicillin is widely regarded as the drug of choice for susceptible strains, including in cases where the organism is vancomycin-resistant, because vancomycin resistance does not affect ampicillin activity.1Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Vancomycin‐Resistant Enterococcal Urinary Tract Infections In practice, many clinicians prescribe amoxicillin (the oral form) for outpatient treatment since it reaches adequate urinary concentrations and is well tolerated.
Nitrofurantoin is a strong second option, particularly for lower UTIs. A study testing 300 enterococcal isolates, including vancomycin-resistant strains, found that none were resistant to nitrofurantoin.2PubMed Central. Nitrofurantoin is active against vancomycin-resistant enterococci A separate analysis of clinical enterococcal isolates found roughly 88% susceptible to nitrofurantoin and about 72% susceptible to ampicillin.3PubMed. In-vitro activity of nitrofurantoin in enterococcus urinary tract infection The catch with nitrofurantoin is that it concentrates in the bladder but does not reach useful levels in the kidneys or bloodstream, so it only works for uncomplicated lower UTIs. If the infection has spread upward, you need something else.
Fosfomycin is another oral option gaining attention. In U.S. surveillance data, the susceptibility rate of E. faecalis to fosfomycin was about 94%, comparable to nitrofurantoin’s rate of roughly 98%.4PubMed Central. Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012 In laboratory models simulating bladder conditions, fosfomycin suppressed regrowth effectively in the majority of E. faecalis isolates.5PubMed Central. Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model Fosfomycin is typically given as a single oral dose for uncomplicated cystitis, which is convenient, though clinical outcome data specific to enterococcal UTIs remain limited compared to data for E. coli.
Why Many Common UTI Antibiotics Do Not Work
If you have ever had a UTI caused by E. coli, your doctor may have prescribed a cephalosporin or trimethoprim-sulfamethoxazole. Neither is useful against E. faecalis. The organism is intrinsically resistant to all cephalosporins, meaning it does not need to acquire any special resistance gene to survive them. Research has traced part of this built-in resistance to a gene called murAA, which is involved in building the bacterial cell wall in a way that cephalosporins cannot effectively disrupt.6Antimicrobial Agents and Chemotherapy. MurAA Is Required for Intrinsic Cephalosporin Resistance of Enterococcus faecalis This is not something that emerged from antibiotic overuse; it is a fundamental feature of the species.
Beyond cephalosporins, E. faecalis has natural low-level resistance to aminoglycosides (like gentamicin) when used alone, and it tolerates sulfonamides and clindamycin. On top of these inborn defenses, enterococci are unusually good at picking up new resistance genes from their environment. They use a diverse set of genetic strategies including modifying drug targets, inactivating antibiotics with enzymes, and pumping drugs out of the cell.7PubMed Central. Mechanisms of antibiotic resistance in enterococci This genetic flexibility is why enterococci have become a leading cause of healthcare-associated infections and why culture-guided therapy, rather than empiric guessing, matters so much when E. faecalis is the pathogen.
One practical takeaway: if you are prescribed a cephalosporin or trimethoprim-sulfamethoxazole and the culture later shows E. faecalis, the antibiotic needs to be changed regardless of whether your symptoms seem to be improving. The improvement may reflect your immune system working rather than the drug working.
Who Is Most Likely to Get an Enterococcal UTI
E. faecalis UTIs are not distributed randomly. They cluster around certain risk factors that set them apart from the typical E. coli bladder infection. A multinational retrospective study identified male sex, age between 55 and 75, catheter use, and urinary retention as independent risk factors for enterococcal UTIs.8PubMed. Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study The association with catheters is particularly strong and drives much of the clinical burden.
Healthcare exposure is a recurring theme. People who have recently been hospitalized, undergone urinary procedures, or received broad-spectrum antibiotics are at elevated risk. Broad-spectrum antibiotics can wipe out competing bacteria in the urinary tract and gut, giving E. faecalis room to flourish. This is part of why enterococcal UTIs are sometimes called “selection pressure infections” — they often follow antibiotic courses aimed at other organisms.
There is also a gut connection worth understanding. Phylogenetic analysis of E. faecalis strains has revealed that urinary isolates are more closely related to gut isolates than to bloodstream isolates, and the two groups share many of the same plasmid types.9mBio. Genetic and functional enrichments associated with Enterococcus faecalis isolated from the urinary tract In other words, the organism typically reaches the urinary tract from your own gastrointestinal flora rather than arriving from an external source. Genes enriched in urinary strains appear to be involved in sugar transport and glucose metabolism, hinting that the ability to use nutrients available in urine gives certain gut strains an advantage once they reach the urinary tract.10mBio. Genetic and functional enrichments associated with Enterococcus faecalis isolated from the urinary tract
Catheter-Associated Infections and Biofilm
Catheter-associated UTIs represent the most clinically challenging subset of E. faecalis urinary infections. The organism forms biofilms on catheter surfaces, which are communities of bacteria encased in a protective matrix that antibiotics penetrate poorly. In animal models, biofilm formation on catheter implants correlated directly with persistent infection, and the enzyme sortase A proved critical for both biofilm formation and virulence in this setting.11PubMed Central. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections
Treating a biofilm-associated infection usually requires removing or replacing the catheter, not just prescribing antibiotics. Antibiotics alone often fail because concentrations that would kill free-floating bacteria cannot penetrate the biofilm deeply enough. Recent laboratory work comparing amoxicillin and ciprofloxacin against E. faecalis biofilms in a catheter model found that ciprofloxacin had markedly greater antibiofilm activity, with the 500 mg daily dose reducing biofilm bacterial counts by more than a thousandfold after 72 hours.12Journal of Antimicrobial Chemotherapy. Assessment of Enterococcus faecalis biofilm response to amoxicillin and ciprofloxacin using a dynamic in vitro pharmacokinetic–pharmacodynamic model of catheter-associated urinary tract infection This does not mean ciprofloxacin is the default choice for all catheter-associated enterococcal UTIs, but it does suggest that amoxicillin or ampicillin alone may struggle when biofilm is established.
For patients with long-term indwelling catheters who develop symptomatic E. faecalis UTIs, the standard approach is to change the catheter and treat with a targeted antibiotic based on susceptibility testing. Simply adding antibiotics without addressing the catheter invites relapse.
When Not to Treat
Finding E. faecalis in a urine culture does not always mean you need antibiotics. Asymptomatic bacteriuria, where bacteria are present in the urine without causing symptoms, is common and frequently overtreated. Infectious disease guidelines generally recommend against treating asymptomatic bacteriuria in most adults, and there is evidence that doing so can actually cause harm. In patients with recurrent UTIs, the presence of asymptomatic E. faecalis in the urine may even have a protective role against future symptomatic infections.13PubMed Central. Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI
The logic is that harmless colonization by a relatively low-virulence organism can prevent more aggressive bacteria from gaining a foothold. Treating the colonization with antibiotics clears this competitive barrier and may paradoxically increase the risk of a symptomatic infection down the line. A study examining enterococcal bacteriuria episodes found that distinguishing between true UTI and asymptomatic bacteriuria required careful assessment of symptoms including urgency, frequency, pain, fever, and flank tenderness, with antibiotic use deemed appropriate only when these symptoms were present and not attributable to another cause.14JAMA Internal Medicine. Overtreatment of Enterococcal Bacteriuria
The exceptions where asymptomatic bacteriuria should be treated include pregnancy and patients about to undergo urologic procedures. Outside these situations, a positive culture for E. faecalis without symptoms is usually best left alone.
Treating Severe and Complicated Infections
When E. faecalis infection moves beyond the bladder to the kidneys, enters the bloodstream, or occurs in a patient with structural urinary abnormalities, the situation escalates. Nitrofurantoin and fosfomycin are no longer adequate because they do not achieve sufficient levels outside the lower urinary tract. Intravenous ampicillin becomes the backbone of therapy. For severe infections, combination therapy with ampicillin plus ceftriaxone is considered a first-line regimen.15Antimicrobial Agents and Chemotherapy. Pharmacokinetic/Pharmacodynamic Index Linked to In Vivo Efficacy of the Ampicillin-Ceftriaxone Combination against Enterococcus faecalis
This combination seems counterintuitive given that ceftriaxone has no meaningful activity against E. faecalis on its own. The rationale is that the two drugs bind to different targets on the bacterial cell wall and produce a synergistic effect greater than either drug alone. The combination has become particularly important for serious enterococcal infections like endocarditis and is increasingly used for complicated UTIs where bacteremia is present or suspected.
Early research showed that adhesive strains of E. faecalis causing UTIs could invade the kidneys, enter the bloodstream, and potentially colonize heart valves.16Infection and Immunity. Role of adherence in pathogenesis of Enterococcus faecalis urinary tract infection and endocarditis While this progression is uncommon, it underscores why complicated enterococcal UTIs require aggressive treatment rather than the wait-and-see approach appropriate for simple cystitis. Pili on the surface of E. faecalis, encoded by the ebp gene cluster, are a major contributor to the organism’s ability to colonize the urinary tract, particularly the kidneys. In animal models, strains lacking functional ebpA or ebpC pilus subunits showed roughly a hundredfold reduction in kidney colonization compared to normal strains.17PLoS ONE. Contribution of Individual Ebp Pilus Subunits of Enterococcus faecalis OG1RF to Pilus Biogenesis, Biofilm Formation and Urinary Tract Infection
Vancomycin-Resistant and Multidrug-Resistant Strains
Vancomycin-resistant enterococci (VRE) urinary tract infections present a genuinely difficult treatment challenge. Fortunately, vancomycin resistance is far more common in E. faecium than in E. faecalis. Genomic analysis of urinary E. faecalis isolates found no vancomycin resistance, and resistance to nitrofurantoin and fluoroquinolones was infrequent.18mBio. Genetic and functional enrichments associated with Enterococcus faecalis isolated from the urinary tract Still, vancomycin-resistant E. faecalis strains do exist in some settings, and high-level aminoglycoside resistance, which eliminates the option of synergistic aminoglycoside combinations, has been documented in hospital-acquired enterococcal UTIs.19PubMed Central. High level aminoglycoside resistant enterococci in hospital-acquired urinary tract infections in Mansoura, Egypt
When VRE causes a UTI and the strain is still ampicillin-susceptible, ampicillin remains the treatment of choice.20Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Vancomycin‐Resistant Enterococcal Urinary Tract Infections Nitrofurantoin also retains activity against VRE strains for lower UTIs.21PubMed Central. Nitrofurantoin is active against vancomycin-resistant enterococci For VRE strains that are also ampicillin-resistant, the options narrow to linezolid and daptomycin. A small retrospective comparison of these two agents in VRE UTIs found no significant difference in outcomes, with low failure rates in both groups, though the study was too small to draw firm conclusions.22PubMed Central. Linezolid Compared to Daptomycin for the Treatment of Vancomycin-resistant Enterococcal Urinary Tract Infections Linezolid has the advantage of oral availability. Daptomycin reaches the urine in limited concentrations, which is a theoretical concern, though it appears to work in practice for UTIs in the clinical data available.
Bacteriophage Therapy on the Horizon
The rise of multidrug-resistant enterococci has pushed researchers to explore treatments beyond traditional antibiotics. Bacteriophage therapy, which uses viruses that specifically infect and kill bacteria, is one of the most actively studied alternatives. Phages targeting E. faecalis have shown anti-biofilm activity in laboratory settings, suggesting they could address one of the hardest aspects of enterococcal UTIs.23Scientific Reports. Characterization and anti-biofilm activity of bacteriophages against urinary tract Enterococcus faecalis isolates
One promising approach combines phages with conventional antibiotics. Early research suggests this phage-antibiotic synergy could both improve bacterial killing and reduce the emergence of resistance to either treatment alone.24International Journal of Molecular Sciences. The Combination of Phage Therapy and β-Lactam Antibiotics for the Effective Treatment of Enterococcus faecalis Infections The idea is that bacteria that evolve resistance to the phage become more susceptible to the antibiotic, and vice versa, creating an evolutionary trap. This approach is still in preclinical stages for enterococcal UTIs, but the growing ineffectiveness of existing antibiotics against multidrug-resistant strains is accelerating interest.25The Microbe. Bacteriophage therapy a promising alternative treatment approach for infections caused by multidrug-resistant (MDR) Enterococcus species
Phage therapy for UTIs faces practical hurdles: regulatory frameworks for therapeutic phages are still developing in most countries, phages are highly specific so a panel of different phages may be needed to cover the diversity of E. faecalis strains, and delivery to the urinary tract has not been optimized. Compassionate-use cases have been reported for individual patients with otherwise untreatable infections, but routine clinical availability is likely years away.
Recurrent Enterococcal UTIs and Antibiotic Stewardship
Recurrence is a particular frustration with enterococcal UTIs. Because E. faecalis lives in the gut as a commensal organism, reinfection from the gastrointestinal reservoir can happen repeatedly, especially in people with ongoing risk factors like catheter use or urinary retention. Each course of antibiotics puts selective pressure on the gut flora, potentially making future enterococcal strains harder to treat. This cycle is one reason infectious disease specialists emphasize confirming that the patient truly has a symptomatic infection before starting treatment.
For people with recurrent culture-positive episodes, a few principles help guide management. Addressing modifiable risk factors, such as removing or replacing catheters and managing urinary retention, is more important than choosing the perfect antibiotic. Cultures should guide every treatment course, because resistance patterns can shift between episodes. Prolonged or suppressive antibiotic therapy is occasionally considered but carries the risk of selecting for more resistant organisms and is generally reserved for patients who cannot have their underlying risk factors corrected. The overtreatment problem is real: enterococcal bacteriuria is one of the clinical scenarios where antibiotics are most frequently prescribed unnecessarily, and each unnecessary course contributes to the very resistance that makes these infections difficult when they do require treatment.